NRXP all time low! 2 X Phase 3 clinical trials!

NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.

52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.

My price target is 16.50

If this is not the time to buy this stock, then when?!
bigpharmabiotechbuyCoronavirus (COVID-19)Fundamental AnalysisTechnical IndicatorsNRXNRXPnrxpharmaceuticalsPHARMAphase3Trend Analysis

גם על:

כתב ויתור